Prognostic value of immunohistochemical expression of HER-2/neu in patients with lung carcinoma

Open access

Prognostic value of immunohistochemical expression of HER-2/neu in patients with lung carcinoma

Background. The amplification and the overexpression of the Her-2/neu gene have been shown in certain human tumours and are postulated to be important in human carcinogenesis. In this study we evaluated the expression of HER-2/neu gene in patients with lung carcinoma (LC) and assessed its prognostic significance.

Patients and methods. HER-2/neu expression was determined in 127 LC patients using immunohistochemistry (IHC) performed on paraffin-embedded section - Hercep Test™ (DAKO).

Results. The overall HER-2/neu expression was seen in 36 (28.35%) of 127 LC patients. According to the histological type, HER-2/neu overexpression was detected in 12 patients with adenocarcinomas (60%), in 19 patients with squamous cell carcinomas (31.14%), in 4 patients with small cell-lung carcinomas (10%) and in 1 patient with other carcinomas (16.66%). Only in patients with small cell-lung carcinomas HER-2/neu overexpression was in correlation with the stage of the disease (p<0.001). The patients with HER-2/neu positive expression were associated with a significantly shorter survival compared with those who were HER-2/neu negative (log rank, p<0.002).

Conclusions. These observations suggest that HER-2/neu positivity may serve as a prognostic indicator in patients with LC. HER-2/neu plays a role in identifying patients at risk for the shortened survival, who may benefit from a more aggressive therapy.

Silverberg E, Lubera JA. Cancer statistics. CA Cancer J Clin 1988; 38: 5-22.

Evans WK. Rationale for the treatment of nonsmall cell lung cancer. Lung Cancer 1993; 9(Suppl 2): S5-14.

Travis WD, Lubin J, Ries L, Devesa S. United States lung carcinoma incidence trends: declining for the most histologic types among males, increasing among females. Cancer 1996; 77: 2464-70.

Potti A, Willardson J, Forseen C, Ganti AK, Koch M, Hebert B, et al. Predictive role of HER-2/neu overexpression and clinical features an initial presentation in patients with extensive stage small cell lung carcinoma. Lung Cancer 2002; 36: 257-61.

Klijanienko J, Couturier J, Galut M, El-Naggar A, Maciorowski Z, Padoy E, et al. Detection and quantitation by fluorescence in situ hybridization (FISH) and image analysis of Her-2/neu gene amplification in breast cancer fine-needle samples. Cancer 1999; 87: 312-8.

Carraway KL 3rd, Cantley LC. A neu acquaintance for ErbB3 and ErbB4: a role for receptor heterodimerization in growth signaling. Cell 1944; 78: 5-8.

Fernandes A, Hamburger AW, Gerwin BI. ErbB-2 kinase is required for constitutive STAT 3 activation in malignant human lung epithelial cells. Int J Cancer 1999; 83: 564-70.

Shi D, He G, Cao S, Pan W, Zhang HZ, Yu D, et al. Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. Mol Carcinog 1992; 5: 213-8.

Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 42: 1644-6.

Meert AP, Martin B, Paesmans M, Berghmans T, Mascaux C, Verdebout J-M, et al. The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer 2003; 89: 959-65.

Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin Oncol 1999; 26(Suppl 12): 51-9.

Brodowicz T, Wiltschke C, Budinsky AC, Krainer M, Steger GG, Zielinski CC. Soluble HER-2/neu neutralizes biologic effects of anti-HER/2neu antibody on breast cancer cells in vitro. Int J Cancer 1997; 73: 875-9.

Wright C, Angus B, Nisholson S, Sainsbury JR, Cairns JC, Gullick WJ, et al. Expression of the c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989; 49: 2087-90.

Jing X, Kakudo K, Murakami M, Nakamura Y, Nakamura M, Yokoi T, et al. Intraductal spread of invasive breast carcinoma has a positive correlation with c-erb B-2 overexpression and vascular invasion. Cancer 1999; 86: 439-48.

Agus DB, Bunn PA Jr, Franklin W, Garcia M, Ozols RF. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol 2000; 27: 92-100.

Selvaggi G, Scagliotti GV, Torri V, Novello S, Leonardo E, Cappia S, et al. HER-2/neu overexpression in patients with radically resected nonsmall-cell lung carcinoma. Impact on long-term survival. Cancer 2002; 94: 2669-74.

Harpole DH, Marks JR, Richards WG, Herndon JE, Sugarbaker DJ. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. Clin Cancer Res 1995; 1: 659-64.

Han H, Landeneau RJ, Santucci TS, Tung MY, Macherey RS, Shackney SE, et al. Prognostic value of immunohistochemical expression of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer. Hum Pathol 2002; 33: 105-10.

WHO. Histological typing of lung tumors. Am J Clin Pathol 1982; 77: 123-36.

Mountain CF. Revision in the international system for staging lung cancer. Chest 1997; 111: 1710-7.

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the erbB-2/neu oncogene. Science 1987; 235: 177-82.

Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 1991; 27: 1372-5.

Kern JA, Schwartz DA, Nordberg JE, Weiner DB, Greene IM, Torney L, et al. p185 neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990; 50: 5184-91.

Shi D, He G, Cao S, Pan W, Zhang HZ, Yu D, et al. Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. Mol Carcinog 1992; 5: 213-8.

Micke P, Hengstler JG, Ros R, Bittinger F, Metz T, Gebhard S, et al. C-ERB-2 expression in small-cell lumg cancer is associated with poor prognosis. Int J Cancer 2001; 92: 474-9.

Potti A, Ganti AK, Tuchman SA, Sholes K, Lagness E, Koka V, et al. Effect of pesticide exposure on HER-2/neu overexpression seen in patients with extensive stage small cell lung carcinoma. Clin Cancer Res 2003; 9: 4872-6.

Pellegrini C, Falleni M, Marchetti A Cassani B, Miozzo M, Buttitta F, et al. HER-2/neu alterations in non-small cell lung cancer. Clin Cancer Res 2003; 9: 3645-52.

Hsieh CC, Chow KC, Fahn HJ, Tsai CM, Li WY, Huang MH, et al. Prognostic significance of HER-2/neu overexpression in stage 1 adenocarcinoma of lung. Ann Thorac Surg 1998; 66: 1159-64.

Ossaki T, Mitsudomi T, Oyama T, Nakanishi R, Yasumoto K. Serum level and tissue expression of c-erB-2 protein in lung adenocarcinoma. Chest 1995; 108: 157-62.

Kim YC, Park KO, Kern JA, Park CS, Lim SC, Jang AS, et al. The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients. Lung Cancer 1998; 22: 181-90.

Pfeiffer P, Clausen PP, Andersen K. Lack of prognostic significance of epidermal growth factor receptor and oncoprotein p185 HER-2/neu in patients with systemically untreated non-small cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 1996; 74: 86-91.

Pelosi G, Del Curto B, Dell'Orto P, Pasini F, Veronesi G, Spaggiari L, et al. Lack of prognostic implications of HER-2/neu abnormalities in 345stage I non small cell carcinomas and 207 stage I-III neuroendocrine tumours of the lung. Int J Cancer 2004; 113: 101-8.

Pastorino U, Andreola S, Tagliabue E, Pezzela F, Incarbone M, Sozzi G, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 1997; 15: 2858-65.

Slamon DJ, Godolphin W, Jones LA. Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.

Tsai CM, Chang KT, Wu LH, Chen JY, Gazdar AF, Mitsudomi T, et al. Correlation between intrinsic chemoresistance and HER-2/neu gene expression, p53gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res 1996; 56: 206-9.

Radiology and Oncology

The Journal of Association of Radiology and Oncology

Journal Information


IMPACT FACTOR 2017: 1.722
5-year IMPACT FACTOR: 1.729

CiteScore 2017: 1.84

SCImago Journal Rank (SJR) 2017: 0.574
Source Normalized Impact per Paper (SNIP) 2017: 0.814


Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 145 144 7
PDF Downloads 30 30 2